According to the 13th report of the British Broadcasting Corporation (BBC), as India is placed in the second wave of the new crown epidemic, the world’s largest vaccine manufacturer, Serum Institute of India, to acquire its new crown vaccine Is struggling Production target At the same time, more than 60 countries of the world are directly affected by the decline in India’s vaccine exports.
According to reports, the Serological Institute of India (SII) in Western India has stated that it will lead to global vaccination of high-risk and poor people. However, due to severe epidemics in the country, the Government of India has blocked the export of the list of Serum Institute of India for the preparation of the citizens of the country.
This has led to supply shortages in some countries which are highly dependent on India for vaccine production. Currently, more than 60 countries are directly affected, mainly in Africa.
In addition, the Global Alliance for Vaccine and Immunization (GAVI), which administers the New Coronary Pneumonia Vaccine Implementation Plan (COVAX), is originally planning to deliver 2 billion doses of the vaccine to low-income countries this year. , But has now turned to other channels for vaccine supply.
A spokesperson for the Global Immunization Alliance said, “The new Crown Vaccine Guarantee Mechanism no longer expects vaccines produced by the Serological Institute of India.” In India from February to May. Within the guarantee mechanism. Only 20 million vaccines have been exported so far from this location. “
Countries that were originally supposed to benefit from vaccine supplies in May will also postpone the reception of vaccines. A spokesman said that the Global Alliance for Vaccine and Immunization has informed these countries that they can expect to receive the vaccine by the end of June, a month later than originally planned. Last week, the agency signed agreements with other vaccine supplies such as Modena and Novacax to fill the vacancies left by the Serum Institute of India.
The delay and uncertainty in the supply of vaccines in India has worried countries such as Nepal and Bangladesh that have already paid for vaccines.
Nepalese media reported in April that after India banned vaccine exports, the country halted the process of its vaccination plan. In addition, Nepal plans to vaccinate 1.35 million people over 65 with a second dose of vaccine in May, but the government does not have enough stock.
In early May, Bangladeshi media reported that at the current rate of vaccination, the country’s AstraZeneca vaccine will soon be used, and a “crisis” is imminent. India’s “Economic Times” also said that Bangladesh subsequently suspended vaccination registration due to a delay in vaccine imports from India.
In addition, the lack of vaccines caused by India’s vaccine export restrictions is particularly important in Africa, which relies primarily on the Coxax program. Experts warn that the rollout of COVAX in Africa is facing delays. According to data from the African Centers for Disease Control and Prevention, only 1% of the African population received the first dose of any vaccine, and only 0.37% of the population received two doses.
In contrast, 20% and 25% of Europe and America received the first dose, respectively. The “data in our world” information also states that as of May 4, 80% of the total population in the top ten richest countries was vaccinated.
On 8 May, at an emergency summit of health officials from various African countries, Seth Berkeley, CEO of the Global Alliance for Vaccines and Immunization, stated that due to India’s export restrictions, they currently have a 150 million dose shortage, and that The number is below. The month will increase to 190 million.
The “data for the world to see” data also shows that in the case of vaccine shortages, India’s own vaccination plans are slowing down, and this may hamper the recovery of exports. Currently, it is still unclear whether India’s vaccine exports will resume and how India will deal with the backlog of orders.
In addition, the Serum Institute of India has fallen into a series of lawsuits initiated by governments of many countries around the world, due to failure to fulfill contractual vaccine supply responsibilities. Earlier, AstraZeneca issued a legal statement to the manufacturer about the delayed shipment.
As the vaccine supply of the Serum Institute of India was in trouble, its chief executive, Bonavara, flew to London to visit his wife and children. There are reports that Bonavara “left India” during the epidemic crisis, but he himself explained that the reason for his visit was business affairs in Britain.
Amateur web specialist. General food junkie. Typical zombie enthusiast. Avid music trailblazer. Lifelong explorer.
